[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640670":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":44,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":80,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"THYROSCOPE INC.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TED - Non-surgical treatment cohort",null,"Adults with TED initiating non-surgical treatment who perform smartphone-based self-monitoring (weekly symptom entry + facial image capture) during the treatment course, with clinic-matched assessments at routine visits.",[13],"Device: Smartphone-based AI self-monitoring application (Glandy CAS\u002FEXO\u002FLID)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Smartphone-based AI self-monitoring application (Glandy CAS\u002FEXO\u002FLID)","A smartphone application through which participants complete a symptom questionnaire (diplopia; pain by visual analog scale) and capture a standardized frontal facial photograph at least weekly during the treatment course, and additionally at each routine clinic visit. Submitted images are transmitted to a central analysis system for AI-based processing that generates three analytic outputs:\n\n* Glandy CAS - CAS-related output derived from periocular signs and symptom input\n* Glandy EXO - image-based exophthalmometric estimate (surrogate of Hertel)\n* Glandy LID - eyelid-related parameters including MRD1\u002FMRD2 equivalents AI outputs are used for research analysis only and are NOT returned to the treating clinician for real-time decision-making during the study.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Jaemin Park","CONTACT","+82 52-264-4154","jaemin.park@thyroscope.com",[27],{"facility":28,"status":10,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"3003 North First Street #221","San Jose","California","95134","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-121.89496,37.33939,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":43,"phoneExt":10,"email":25},"Jaemin Park CEO","+82-52-264-4154",{"type":45,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100640670","prospective-observational-study-of-smartphone-based-ai-self-monitoring-during-non-surgical-treatment-for-thyroid-eye-disease-thyroscope-100640670",false,"NCT07623993","Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE)","Prospective Observational Study of Smartphone-Based Self-Monitoring Using an Artificial Intelligence Solution During Non-Surgical Treatment for Thyroid Eye Disease","THYROSCOPE-TED","Inclusion Criteria:\n\n* Adults aged 19 years or older with a clinical diagnosis of thyroid eye disease (TED).\n* Patients with TED scheduled to initiate active non-surgical treatment, including but not limited to intravenous methylprednisolone, oral corticosteroids, radiotherapy, or biologic therapy.\n* Able to undergo baseline clinical assessment prior to initiation of the planned treatment course and expected routine follow-up evaluation during treatment, including an end-of-treatment assessment.\n* Able and willing to use their own smartphone to complete the study application-guided symptom questionnaire and capture standardized frontal facial images throughout the study period.\n* Willing to perform at least weekly home-based image capture and symptom reporting during the treatment course.\n* Able to participate in routine in-person follow-up visits and expected to provide at least two clinic-matched assessments, including baseline and at least one post-baseline assessment.\n* Voluntarily provides written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Severe eyelid deformities, facial deformities, or other facial\u002Fperiocular conditions that may interfere with standardized image acquisition or reliable AI-based image analysis.\n* Unable to use the study application or smartphone-based image capture procedure adequately for protocol-required self-monitoring.\n* Undergoing or planning to undergo surgical treatment for TED as the primary treatment modality during the study period.\n* History of ocular, eyelid, or orbital surgery within 3 months prior to enrollment.\n* Any medical, psychiatric, cognitive, or other condition that, in the investigator's judgment, may compromise protocol compliance, study participation, or data integrity.\n* Any other condition that the investigator judges to make the patient inappropriate for participation.","ALL","22 Years",{"count":57,"type":58},200,"ESTIMATED","OBSERVATIONAL","This prospective observational study evaluates the feasibility and clinical utility of a smartphone-based artificial intelligence (AI) self-monitoring system in adults with thyroid eye disease (TED) undergoing non-surgical treatment. Eligible participants will use their own smartphones and the study application (Glandy) to perform at least weekly home monitoring consisting of a symptom questionnaire (diplopia, pain on visual analog scale) and a standardized frontal facial photograph. AI-derived outputs (Glandy CAS, Glandy EXO, Glandy LID) obtained at routine clinic visits will be compared with standard clinician assessments (CAS total score, Hertel exophthalmometry, MRD1\u002FMRD2). AI outputs will not be used for real-time clinical decision-making during the study.",[62,63,64],"Thyroid Eye Disease (TED)","Graves Ophthalmopathy","Thyroid Associated Ophthalmopathies",[66,67,68,69,70,71,72,73,74,75,76,77,78,79],"Thyroid eye disease","TED","Graves orbitopathy","Artificial intelligence","Smartphone","Self-monitoring","Clinical Activity Score","CAS","Exophthalmometry","MRD1","MRD2","Remote monitoring","Digital health","Telemedicine","NOT_YET_RECRUITING","2026-05-28",{"date":83,"type":84},"2026-06-03","ACTUAL",{"date":86,"type":58},"2026-07-01",{"date":88,"type":58},"2027-12-31",{"name":5,"class":6},1]